主页 /
搜索结果：“jwh 018”

“jwh 018”的搜索结果

Quick View
NS-018 maleate

Catalog No. A16226
Quick View

添加到收藏
JAK2 抑制剂

NS-018 maleate是在Ba/F3-JAK2V617F细胞中具有ATP竞争性的JAK2小分子抑制剂，IC50为470nM。与其他JAK家族激酶（例如JAK1，JAK3和酪氨酸激酶2）相比，对JAK2的选择性高30-50倍。了解更多

Bulk Inquiry
Quick View
NS-018 hydrochloride

Catalog No. A16225
Quick View

添加到收藏
JAK2 抑制剂

NS-018 hydrochloride是一种新型的高选择性JAK2抑制剂。了解更多

Bulk Inquiry
Quick View
NS-018

Catalog No. A16224
Quick View

添加到收藏
JAK2 抑制剂

NS-018是Janus相关激酶2（JAK2）和Src家族激酶的口服生物利用型小分子抑制剂，具有潜在的抗肿瘤活性。了解更多

Bulk Inquiry
Quick View
GNE-955

Catalog No. A19243
Quick View

添加到收藏
Pim kinase inhibitor

GNE-955 is a potent and orally active pan Pim kinase inhibitor with Kis of 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively. 了解更多

Bulk Inquiry
Quick View
Ruxolitinib sulfate

Catalog No. A11467
Quick View

添加到收藏
JAK1/2 inhibitor

Ruxolitinib sulfate (INCB018424 sulfate) is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC50s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3. 了解更多

Bulk Inquiry
Quick View
JAK1-IN-7

Catalog No. A19029
Quick View

添加到收藏
JAK1 抑制剂

JAK1-IN-7 is a Janus-associated kinase 1 (JAK1) inhibitor extracted from patent WO2018134213A1, Example 63, has an anti-inflammatory effect. 了解更多

Bulk Inquiry
Quick View
Ruxolitinib Phosphate

Catalog No. A11552
Quick View

添加到收藏
JAK 抑制剂

Ruxolitinib Phosphate是ruxolitinib的磷酸盐形式，ruxolitinib是一种口服生物可利用的Janus相关激酶(JAK)抑制剂，具有潜在的抗肿瘤和免疫调节活性。了解更多

Bulk Inquiry
Quick View
TCS 21311

Catalog No. A15365
Quick View

添加到收藏
JAK3 抑制剂

TCS 21311是有效的JAK3抑制剂（IC50 = 8 nM）。TCS 21311对于JAK3相对于JAK1，JAK2和Tyk 2具有选择性（IC50值分别为1017、2550和8055 nM）。了解更多

Bulk Inquiry
Quick View
S-Ruxolitinib

Catalog No. A14955
Quick View

添加到收藏
JAK 抑制剂

S-Ruxolitinib是INCB018424的手性化合物，是一种有效且选择性的小分子Janus激酶1（JAK1）和JAK2抑制剂。了解更多

Bulk Inquiry
Quick View
INCB018424 (Ruxolitinib)

Catalog No. A11041
Quick View

添加到收藏
JAK1/2 抑制剂

INCB018424 (Ruxolitinib)是有效和选择性的Janus相关激酶JAK1/2抑制剂，对JAK1，JAK2和JAK3的IC50分别为2.7、4.5和332 nM。了解更多

Product Citations (6)

Bulk Inquiry Free Sample
- Aya Hasan Alshammari, .et al. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition, Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812
- Daniel Doheny, .et al. Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis, Oncogene, 2020, Oct;39(42):6589-6605 PMID: 32929154
- Rasmus Siersbek, .et al. IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis, Cancer cell, 2020, Jul 6;S1535-6108(20)30311-1 PMID: 32679107
- Brittany M. Duggan, .et al. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia, Sci Rep, 2017, 7: 1578 PMID: 28484277
- Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
- Kagoya Y, .et al. JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2., Blood., 2014, Nov 6;124(19):2996-3006 PMID: 25217696